[{"id":"93f98008-2763-4eb8-b3d9-f6477ef24b99","acronym":"FURMO-002","url":"https://clinicaltrials.gov/study/NCT05364073","created_at":"2022-05-06T18:55:07.280Z","updated_at":"2024-07-02T16:35:02.618Z","phase":"Phase 1","brief_title":"Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations","source_id_and_acronym":"NCT05364073 - FURMO-002","lead_sponsor":"ArriVent BioPharma, Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 exon 20 insertion • EGFR G719X • EGFR S768I • EGFR G724S • HER-2 exon 23 mutation • EGFR R776C • EGFR V774M","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 exon 20 insertion • EGFR G719X • EGFR S768I • EGFR G724S • HER-2 exon 23 mutation • EGFR R776C • EGFR V774M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ivesa (firmonertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 170","initiation":"Initiation: 06/30/2022","start_date":" 06/30/2022","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-05-20"}]